{"id":162844,"date":"2023-04-26T16:22:19","date_gmt":"2023-04-26T21:22:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/04\/alzheimers-proteins-reduced"},"modified":"2023-05-01T00:05:45","modified_gmt":"2023-05-01T05:05:45","slug":"alzheimers-proteins-reduced","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/04\/alzheimers-proteins-reduced","title":{"rendered":"Alzheimer\u2019s Proteins Reduced by Sleep Drug"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/alzheimers-proteins-reduced2.jpg\"><\/a><\/p>\n<p>Suvorexant (Belsomra), a dual orexin receptor antagonist approved for insomnia, reduced levels of tau phosphorylation and amyloid beta, a small clinical trialopens in a new tab or window showed.<\/p>\n<p>The ratio of phosphorylated tau-threonine-181 (p-tau-181) to unphosphorylated tau-threonine-181 decreased 10% to 15% in cognitively normal adults treated with suvorexant 20 mg compared with placebo, reported Brendan Lucey, MD, MSCI, of Washington University School of Medicine in St. Louis, and co-authors.<\/p>\n<p>Amyloid-beta levels fell 10% to 20% compared with placebo starting 5 hours after suvorexant administration, the researchers wrote in Annals of Neurologyopens in a new tab or window.<\/p>\n<hr>\n<p>\u2014 Both amyloid and tau levels fell in early trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suvorexant (Belsomra), a dual orexin receptor antagonist approved for insomnia, reduced levels of tau phosphorylation and amyloid beta, a small clinical trialopens in a new tab or window showed. The ratio of phosphorylated tau-threonine-181 (p-tau-181) to unphosphorylated tau-threonine-181 decreased 10% to 15% in cognitively normal adults treated with suvorexant 20 mg compared with placebo, reported [\u2026]<\/p>\n","protected":false},"author":461,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-162844","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/162844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/461"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=162844"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/162844\/revisions"}],"predecessor-version":[{"id":163118,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/162844\/revisions\/163118"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=162844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=162844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=162844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}